Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging single-dose glycopyrrolate inhalation solution in COPD
2010-018987-17Phase 2Completed
- Sponsor
- Elevation Pharmaceuticals, Inc.
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Elevation Pharmaceuticals, Inc. Primary endpoints: Trough FEV1 at 24 hours, FEV1 area under the curve (AUC) and 2 more. Started Jun 2010; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-018987-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018987-17.